New Advancement Distinguishes Reoccurring Prostate Cancer 🖤

In 2016, about 30% of men who have surgery anticipated to cure localized prostate cancer 🖤  will still have a recurrence, according to the researchers. Normally, doctors monitor for recurring cancer using blood tests for levels of prostate-specific antigen (PSA). PSA levels after surgery should be close to zero, and rising levels suggest the cancer has returned. If PSA levels are very high, then finding where the cancer has spread is usually apparent. But when the PSA level rises just a little, standard imaging tests often cannot detect where that spread has occurred.

To help define the exact areas of cancer spread in men who had a slight increase in PSA, the researchers consolidated two scanning technologies: C-11 choline PET scanning and multiparametric MRI. The combination of the two tests helped identify whether the spread was just around the area of the original surgery or farther away.

The advanced imaging technologies may allow for quicker detection of spreading cancer, regardless of its location, than conventional imaging and thus help men get early treatment.

  • Share: